A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

The next generation of scientists are digital natives ready to problem solve and innovate

by Juergen A. Klenk, Ph.D, Principal, Deloitte Consulting LLP

This week Deloitte and the National Institutes of Health’s National Library of Medicine (NLM) will recognize two student-led research teams from San Diego State University (SDSU) and Kingsborough Community College of The City University of New York (KCC CUNY) for their groundbreaking research in the Microbial Metagenomics Discovery Challenge.

The undergraduate students’ work was impressive by any standard.

Read more

Risk-based contracting: It’s NOT just about the shared savings

by Mark Bethke, FSA, MAAA, Managing Director, Deloitte Consulting LLP

The first in a blog series to guide provider organizations through strategic risk contracting for population health

As health systems (hospitals and provider organizations) continue to transition to value-based care and population health, more and more contracts with payers are including some form of gain/risk sharing. Even if a system has not yet taken on any risk,

Read more

A little less conversation (a little more action) in outcomes-based contracts?

by Mary Cummins, Principal, Deloitte Consulting LLP

I’m recently back from AdvaMed’s annual conference where, as always, I was struck by the deep commitment to bring innovation to patients. But innovation is in the eye of the beholder. When it comes to medtech offerings, there are many stakeholders who decide if an innovation is going to deliver differentiated results, and what value is merited in return.

Read more

DNA-based Zika virus vaccine moves forward in US

by Doug Beaudoin, Principal, Deloitte Consulting LLP

The Zika virus that has caused an epidemic of birth defects in parts of Latin America and the Caribbean receded from the headlines here in the US once cooler weather rolled in last fall. But, as certain parts of the country gear up for mosquito season, public health officials are reminding residents and travelers to prepare and take precautions,

Read more

What does the new administration mean for life sciences companies?

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Shortly after the election, the life sciences industry was wondering what was coming next. President Trump had not mentioned federal negotiation of Medicare drug prices in a while, state efforts to pass pricing legislation had failed, the outgoing Obama Administration had announced it would not move forward with the demonstration for regulating physician-administered drugs under Medicare Part B,

Read more